Oxford BioDynamics (OBD) Competitors

Oxford BioDynamics (LON:OBD) and Sareum (LON:SAR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Which has more risk & volatility, OBD or SAR?

Oxford BioDynamics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500. Comparatively, Sareum has a beta of -1.08, indicating that its share price is 208% less volatile than the S&P 500.

Do institutionals & insiders believe in OBD or SAR?

11.4% of Oxford BioDynamics shares are held by institutional investors. 15.5% of Oxford BioDynamics shares are held by insiders. Comparatively, 36.6% of Sareum shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the media prefer OBD or SAR?

In the previous week, Oxford BioDynamics and Oxford BioDynamics both had 1 articles in the media. Oxford BioDynamics' average media sentiment score of 0.75 beat Sareum's score of 0.67 indicating that Oxford BioDynamics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oxford BioDynamics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sareum	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is OBD or SAR more profitable?

Sareum has a net margin of 0.00% compared to Oxford BioDynamics' net margin of -1,800.32%. Sareum's return on equity of -270.25% beat Oxford BioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford BioDynamics	-1,800.32%	-289.38%	-56.23%
Sareum	N/A	-270.25%	-113.80%

Which has better earnings & valuation, OBD or SAR?

Sareum has lower revenue, but higher earnings than Oxford BioDynamics. Sareum is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford BioDynamics	£896K	10.33	-£103.52M	-£0.03	-16.31
Sareum	N/A	N/A	-£5.28M	-£0.03	-1,022.12

Summary

Oxford BioDynamics beats Sareum on 6 of the 11 factors compared between the two stocks.